V-PLEX Human MIP-3α Kit

V-PLEX Plus Human MIP-3α Kit Overview
The V-PLEX Plus Human MIP-3α Kit is optimized for long-term and multi-site biomarker studies that require reliable, reproducible results with lot-to-lot consistency. The V-PLEX Plus Human MIP-3α Kit enables the sensitive detection of native MIP-3α in multiple sample types including serum, plasma, urine, cell culture supernatants, and PBMCs. To learn more about the advantages of V-PLEX assays click here.
The V-PLEX Plus Human MIP-3α assay is available as an individual assay as well as in a multiplex combination with other TH17-related analytes in the V-PLEX TH17 Panel 1 (human) Kit (catalog # K15085G, K15085D).
All V-PLEX kits come with coated plates, calibrators, labeled detection antibodies, optimized diluents, a comprehensive product insert, and a certificate of analysis. V-PLEX Plus kits also include controls, wash buffer, and plate seals for added quality and convenience.

V-PLEX Plus Human MIP-3α Assay Features

  • Validated to measure human MIP-3α in serum, plasma, cell culture supernatants, PBMCs, and urine
  • Dynamic range: 0.050 pg/mL – 325 pg/mL
  • LLOQ: 0.588 pg/mL

Typical Data
Calibration curve accuracy and precision for the V-PLEX Plus Human MIP-3α assay were assessed and representative data are presented below.

Figure 1. V-PLEX Plus Human MIP-3α Calibration Curve
Human MIP-3α Calibrator Curve
Figure 2. V-PLEX Plus Human MIP-3α Data
Human MIP-3α Calibrator Curve Data
MIP-3α Analyte

Description - Macrophage inflammatory protein 3-alpha (MIP-3α) is a C-C chemokine with inflammatory and homeostatic functions. Initially identified in the liver, MIP-3α is expressed in lymphatic tissue, lung tissue, macrophages, dendritic cells, B- and T-lymphocytes, and eosinophilic granulocytes as well as in normal colon, pancreas, prostate, uterine cervix, and skin. To date, MIP-3α is the only known ligand for the CCR6 receptor; it is also chemotactic for CCR6+ cells such as TH17. MIP-3α is implicated in a broad spectrum of disorders, including colorectal cancer and tumor metastasis, rheumatoid arthritis, psoriasis, obesity, and wound healing. Disrupting the MIP-3α and CCR6 interaction may ultimately prove to be a viable therapeutic strategy, as CCR6 deletion resulted in a reduced atherosclerotic lesion area and reduced macrophage presence at atherosclerotic plaque sites in models of atherogenesis.

Disease Focus - Inflammatory diseases, including colorectal cancer and tumor metastasis, rheumatoid arthritis, psoriasis, obesity, and wound healing.

Application Area - Inflammation, cytokines and chemokines

  • Specifications
  • Kit Contents
  • Resources
Order Details
Catalog No
Size
Price in USD
Qty
K151XDD-1
1 ea
$371.00
K151XDD-2
5 ea
$1,577.00
K151XDD-4
25 ea
$6,493.00
Customer Service/Orders


Scientific/Technical Support


Instrument Support


Company Headquarters